Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received. Pursuant to the terms of the Agreement, Ascentage Pharma has allotted and issued an aggregate of 24,307,322 subscription shares to Takeda International at the share purchase price of HK$24.09850 (equivalent to approximately US$3.08549).

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO

Ascentage Pharma announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of American depositary shares representing its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to occur after the SEC completes its review process, subject to market and other conditions.